Metagenomi initiated with an Overweight at Wells Fargo

Wells Fargo initiated coverage of Metagenomi with an Overweight rating and $25 price target. The analyst says Metagenomi’s full-spectrum, fit-for-purpose gene editing toolbox positions it well for expanding the horizon of gene editing applications. The firm sees a high likelihood of success for the company’s lead hemophilia A program. Metagenomi’s proprietary editing platform coupled with its modular engineering system offers wide-ranging and differentiated editing capabilities, the analyst tells investors in a research note.